143 related articles for article (PubMed ID: 8541098)
1. Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer.
Gurney H; Harnett P; Stuart-Harris R; Kefford R
Eur J Cancer; 1995 Oct; 31A(11):1773-7. PubMed ID: 8541098
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin.
Gurney H; Harnett P; Kefford R; Boyages J
Aust N Z J Med; 1998 Jun; 28(3):400-2. PubMed ID: 9673758
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide, mesna and epirubicin as second-line chemotherapy in advanced breast cancer.
Kiraz S; Baltali E; Güler N; Barista I; Benekli M; Celik I; Güllü IH; Kars A; Tekuzman G; Firat D
J Chemother; 1996 Aug; 8(4):310-4. PubMed ID: 8873839
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Ghavamzadeh A
Cancer Chemother Pharmacol; 1990; 26 Suppl():S66-8. PubMed ID: 2347052
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide, vincristine, doxorubicin and dacarbazine in adult patients with advanced soft-tissue sarcoma.
Wiklund TA; Blomqvist CP; Virolainen M; Elomaa I
Cancer Chemother Pharmacol; 1992; 30(2):100-4. PubMed ID: 1600589
[TBL] [Abstract][Full Text] [Related]
7. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.
Rodriguez MA; Cabanillas FC; Velasquez W; Hagemeister FB; McLaughlin P; Swan F; Romaguera JE
J Clin Oncol; 1995 Jul; 13(7):1734-41. PubMed ID: 7602363
[TBL] [Abstract][Full Text] [Related]
8. The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Lind MJ; Gumbrell L; Cantwell BM; Millward MJ; Simmonds D; Proctor M; Chapman F; McCann E; Middleton I; Calvert AH
Br J Cancer; 1995 Mar; 71(3):610-3. PubMed ID: 7533518
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.
Langenbuch T; Mross K; Jonat W; Hossfeld DK
Cancer Chemother Pharmacol; 1990; 26 Suppl():S93-6. PubMed ID: 2347058
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
[TBL] [Abstract][Full Text] [Related]
12. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Murad AM; Guimaraes RC; Amorim WC; Morici AC; Ferreira-Filho AF; Schwartsmann G
Breast Cancer Res Treat; 1997 Aug; 45(1):47-53. PubMed ID: 9285116
[TBL] [Abstract][Full Text] [Related]
14. The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer.
Cantwell BM; Bozzino JM; Corris P; Harris AL
Eur J Cancer Clin Oncol; 1988 Feb; 24(2):123-9. PubMed ID: 2833398
[TBL] [Abstract][Full Text] [Related]
15. A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy.
Sørensen P; Pfeiffer P; Bertelsen K
Gynecol Oncol; 1995 Jan; 56(1):75-8. PubMed ID: 7821851
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Unsal M; Erturk D
Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
[TBL] [Abstract][Full Text] [Related]
17. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
18. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
20. Epidoxorubicin plus ifosfamide in advanced and/or metastatic soft-tissue sarcomas.
Toma S; Coialbu T; Biassoni L; Folco U; Gatti C; Canavese G; Giacchero A; Rosso R
Cancer Chemother Pharmacol; 1990; 26(6):453-6. PubMed ID: 2121378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]